Bevacizumab plus irinotecan therapy in relapsed, heavily pre-treated malignant glioma: A case series

被引：0
|
作者：
Friedland, D. M. [1 ]
Ali, S. A. [1 ]
Ahmad, A. [1 ]
Rahman, M. [1 ]
Bejjani, G. [1 ]
Braffet, M. [1 ]
机构：
[1] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12500
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient
    Deeks, SG
    Martin, JN
    AIDS, 2001, 15 (01) : 117 - 119
  • [42] Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis
    Artene, Stefan-Alexandru
    Turcu-Stiolica, Adina
    Hartley, Richard
    Ciurea, Marius Eugen
    Daianu, Oana
    Brindusa, Corina
    Alexandru, Oana
    Tataranu, Ligia Gabriela
    Purcaru, Stefana Oana
    Dricu, Anica
    ONCOTARGETS AND THERAPY, 2016, 9 : 6669 - 6676
  • [43] The Promising Role of Sunitinib Rechallenge in Heavily Pre-Treated Thymic Carcinoma: A Case Report
    Palmieri, G.
    Ottaviano, M.
    Tortora, M.
    Perrone, P.
    Rea, C.
    De Placido, S.
    Giuliano, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S606 - S606
  • [44] Safety and Efficacy of Tinostamustine in Heavily Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)
    Ghesquieres, Herve
    Pinto, Antonio
    Sureda, Anna
    Tournilhac, Olivier
    Morschhauser, Franck
    Janik, Tomas
    Zinzani, Pier Luigi
    BLOOD, 2021, 138
  • [45] Capecitabine plus gemcitabine in heavily pre-treated colorectal cancer.: Results of an exploratory study.
    Fernández, Y
    Vieitez, JM
    Fra, J
    Palacio, I
    Mareque, B
    Uña, E
    Buesa, JM
    Lacave, AJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 289S - 289S
  • [46] Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study
    Gururangan, Sridharan
    Chi, Susan N.
    Poussaint, Tina Young
    Onar-Thomas, Arzu
    Gilbertson, Richard J.
    Vajapeyam, Sridhar
    Friedman, Henry S.
    Packer, Roger J.
    Rood, Brian N.
    Boyett, James M.
    Kun, Larry E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 3069 - 3075
  • [47] MRI AND FET-PET DEMONSTRATE EARLY RESPONSE TO BEVACIZUMAB AND IRINOTECAN THERAPY IN RECURRENT MALIGNANT GLIOMA
    Schroeteler, J.
    Rapp, M.
    Ringelstein, A.
    Stoffels, G.
    Langen, K.
    Stummer, W.
    Steiger, H.
    Ewelt, C.
    Sabel, M.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1099 - 1099
  • [48] TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial
    Boland, Patrick M.
    Mukherjee, Sarbajit
    Imanirad, Iman
    Vijayvergia, Namrata
    Cohen, Seth D.
    Gupta, Medhavi
    Iyer, Renuka V.
    Bakin, Andrei
    Wang, Jianxin
    Chatley, Sarah
    Cahill, Beth
    Vadehra, Deepak
    Attwood, Kristopher
    Hochster, Howard S.
    Fountzilas, Christos
    BRITISH JOURNAL OF CANCER, 2024, 131 (08) : 1290 - 1297
  • [49] Successful ethinylestradiol therapy for a metastatic breast cancer patient with heavily pre-treated with endocrine therapies
    Aiko Sueta
    Mitsuhiro Hayashi
    Yoshiyuki Fukugawa
    Hirokazu Shimizu
    Mutsuko Yamamoto-Ibusuki
    Yutaka Yamamoto
    Hirotaka Iwase
    International Cancer Conference Journal, 2016, 5 (3) : 126 - 130
  • [50] Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO)
    Boland, Patrick M.
    Mukherjee, Sarbajit
    Imanirad, Iman
    Vijayvergia, Namrata
    Cohen, Seth D.
    Gupta, Medhavi
    Iyer, Renuka V.
    Chatley, Sarah
    Cahill, Beth
    Vadehra, Deepak
    Attwood, Kristopher
    Hochster, Howard S.
    Fountzilas, Christos
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345